JFA
SRPT icon

JNBA Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

JNBA Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$386 – 726
2023
Q4 		$386 Hold
4
– – ﹤0.01% 682
2023
Q3 		$485 Buy
+4
New +$452 ﹤0.01% 704

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JNBA Financial Advisors's SRPT Position: Q1 2024 in Review

JNBA Financial Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 4 shares — an estimated $386 sold.

JNBA Financial Advisors first reported a position in SRPT in Q3 2023 and held it in 2 quarters. The position peaked at $485 in Q3 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • JNBA Financial Advisors reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • JNBA Financial Advisors sold 4 Sarepta Therapeutics shares in Q1 2024, an estimated $386.
  • JNBA Financial Advisors first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 2 quarters.
  • JNBA Financial Advisors's Sarepta Therapeutics position peaked at $485 in Q3 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on JNBA Financial Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.